Tenapanor for the Treatment of Pediatric Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Status:
Enrolling by invitation

Trial end date:
2031-10-01

Target enrollment:

Participant gender:

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

Phase 3

Ardelyx